Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHX2005 in Advanced Solid Tumors
NCT05609019Phase 1Not yet recruiting
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of SYHX2005 in solid tumor (advanced stage), sponsored by CSPC Ouyi Pharmaceutical. Primary endpoints: Maximum Tolerated Dose and Overall Response Rate at 2 years. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
SYHX2005
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05609019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05609019.